Drugs / MVA-NP+M1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03883113 | Jun → Dec 2019 | influenza | Barinthus Biotherapeutics | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-NP+M1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03883113 ↗ |
| Modality | Vaccine | “The use of an MVA vaccine to expand CD4+ or CD8+ T cells to conserved influenza A antigens” PMID 38729196 ↗ May 2024 |
| Route | Intramuscular | “receive 0·5 mL intramuscular injections of modified vaccinia Ankara (MVA)” PMID 38729196 ↗ May 2024 |